Transplant International最新文献_第3页

C1q Binding Ability for Prior Risk Assessment of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation. C1q 结合能力用于 ABO 血型不相容肾移植急性抗体介导排斥反应的预先风险评估。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13407

Yuko Miwa, Kenta Iwasaki, Kenta Murotani, Manabu Okada, Takaharu Nagasaka, Yoshihiko Watarai, Asami Takeda, Masato Shizuku, Satoshi Ashimine, Kohei Ishiyama, Shoichi Maruyama, Takaaki Kobayashi

{"title":"C1q Binding Ability for Prior Risk Assessment of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.","authors":"Yuko Miwa, Kenta Iwasaki, Kenta Murotani, Manabu Okada, Takaharu Nagasaka, Yoshihiko Watarai, Asami Takeda, Masato Shizuku, Satoshi Ashimine, Kohei Ishiyama, Shoichi Maruyama, Takaaki Kobayashi","doi":"10.3389/ti.2024.13407","DOIUrl":"https://doi.org/10.3389/ti.2024.13407","url":null,"abstract":"In ABO blood group incompatible kidney transplantation (ABO-I), potential issues on acute antibody-mediated rejection (ABMR) remain to be solved. This study aimed to assess the risk factors of acute ABMR using recipient- or donor-derived specimens. Quantitative analysis of A/B antigen expression was conducted in 104 donor kidney tissues (Kt), platelets (Plt), and red blood cells (RBC) by immunohistochemical staining or flow cytometry (FCM). ABO-I pre-transplant recipient serum samples (ABMR = 12, non-ABMR = 27) were extracted by propensity score matching. Anti-A antibody titers of IgM, IgG and IgG subclasses, and C1q binding ability (%) on antibody were measured using RBC-FCM. No association was observed between ABMR and A/B antigen expression levels in donor's Plt, RBC, or Kt. In recipient's sample, C1q-IgG binding ability was significantly higher in the ABMR group than in the non-ABMR group (C1q-IgG: 9.04% vs. 5.93% p = 0.049). Neither the A/B antigen expression level in donors (grafts) nor anti-blood group IgG/IgM antibodies in recipient sera before desensitization seemed to influence ABMR incidence in ABO-I. In contrast, C1q-IgG binding ability could be a potential predictor for ABMR in ABO-I.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13407"},"PeriodicalIF":2.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142547717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Complement, Coagulation, and Fibrinolysis: The Role of the Endothelium and Its Glycocalyx Layer in Xenotransplantation. 补体、凝血和纤溶：内皮及其糖萼层在异种移植中的作用。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13473

Mitra Gultom, Robert Rieben

引用次数: 0

Transplant Trial Watch. 移植试验观察。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-14 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13860

Simon R Knight, John M O'Callaghan

引用次数: 0

Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport^® Can Be Anticipated. 可以预测接受 Adoport® 治疗的新成人肾移植患者对他克莫司剂量的需求。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-14 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13495

Pierre Marquet, Dany Anglicheau, Antoine Humeau, Sofian Adrouche, Lakhdar Saada, Julie Bisiaux, Sara Guillemin, Audrey Lardy-Cléaud, Lionel Rostaing

{"title":"Tacrolimus Dose Requirement in De Novo Adult Kidney Transplant Patients Treated With Adoport® Can Be Anticipated.","authors":"Pierre Marquet, Dany Anglicheau, Antoine Humeau, Sofian Adrouche, Lakhdar Saada, Julie Bisiaux, Sara Guillemin, Audrey Lardy-Cléaud, Lionel Rostaing","doi":"10.3389/ti.2024.13495","DOIUrl":"10.3389/ti.2024.13495","url":null,"abstract":"All the factors potentially influencing tacrolimus dose requirement and combinations thereof have never been thoroughly investigated, precluding accurate prediction of tacrolimus starting dose. This prospective, non-interventional, multicenter study in de novo adult kidney transplant recipients over the first year after transplantation aimed to investigate the factors influencing tacrolimus dose-standardized trough blood concentration (C0/D) over the first week post-transplant (D4-D7, primary objective), D8-M3 and M3-M12 (secondary objectives). Statistical analysis employed mixed linear models with repeated measures. Eighteen sites enrolled 440 patients and followed them up for 9.5 ± 4.1 months. Age at baseline (p = 0.0144), end-stage renal disease (p = 0.0092), CYP3A phenotype (p < 0.0001), dyslipidemia at baseline (p = 0.0031), hematocrit (p = 0.0026), total bilirubin (p = 0.0261) and plasma creatinine (p = 0.0484) independently increased with log(C0/D) over D4-D7, explaining together 72.3% of the interindividual variability, and representing a robust model to estimate tacrolimus initial dose. Donor age and CYP3A phenotype were also influential over D8-M3 and M3-12, in addition to recipient age. Corticosteroids, diabetes at baseline, and ASAT yielded inconstant results between D8-M3 and M3-M12. We found no ethnicity effect when CYP3A phenotype was accounted for, and no food effect. Intra-individual variability over M3-M12 was moderate, and significantly lower in patients with chronic hepatic disorder (p = 0.0196) or cancer (p = 0.0132).","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13495"},"PeriodicalIF":2.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142523237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ESOT Roadmap for Advanced Therapy Medicinal Products in Transplantation: Navigating Regulatory Challenges to Enhance Access and Care. ESOT 移植中的先进治疗药物路线图：应对监管挑战，提高治疗机会和护理水平。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-14 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13485

Ekaterine Berishvili, Lorenzo Piemonti, Eelco J P de Koning, Sandra Lindstedt, Hanne Scholz, William E Scott, Celine Auxenfans, Paul Johnson, Dominique E Martin, Penilla Gunther, Devi Mey, Luciano Potena, Olivier Thaunat

{"title":"ESOT Roadmap for Advanced Therapy Medicinal Products in Transplantation: Navigating Regulatory Challenges to Enhance Access and Care.","authors":"Ekaterine Berishvili, Lorenzo Piemonti, Eelco J P de Koning, Sandra Lindstedt, Hanne Scholz, William E Scott, Celine Auxenfans, Paul Johnson, Dominique E Martin, Penilla Gunther, Devi Mey, Luciano Potena, Olivier Thaunat","doi":"10.3389/ti.2024.13485","DOIUrl":"10.3389/ti.2024.13485","url":null,"abstract":"The field of organ transplantation is experiencing a transformative shift with the rise of Advanced Therapy Medicinal Products (ATMPs), which include gene therapies, somatic cell therapies, and tissue-engineered products. These therapies offer new, potentially curative treatments for longstanding medical challenges, impacting numerous patients. However, their adoption is hindered by complex regulatory frameworks, high production costs, and inconsistent access across Europe. The ESOT ATMP Task Force's position paper analyzes these challenges from research to clinical application, advocating for a coordinated strategy to position Europe as a leader in ATMP development. It proposes specific actions such as streamlining regulatory pathways to accelerate approvals, boosting funding for ATMP research, and creating specialized facilities for development and implementation. The paper also highlights the critical roles of patient engagement and real-world evidence in optimizing clinical and regulatory practices.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13485"},"PeriodicalIF":2.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142524079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current Challenges and Advances on Infectious Diseases in Solid Organ Transplantation. 当前实体器官移植感染性疾病的挑战与进展。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13856

Mario Fernández-Ruiz, Maddalena Giannella, Ilkka Helanterä, Oriol Manuel, Ligia Camera Pierrotti, Dafna Yahav

引用次数: 0

Diversity, Equity, and Inclusion in Transplantation. 移植手术中的多样性、公平性和包容性。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-09 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13832

Maria Irene Bellini, Chloe Balleste, Paulo N Martins, Ifeoma Ulasi, Hannah Valantine, Luciano Potena

引用次数: 0

Monitoring for PERV Following Xenotransplantation. 异种器官移植后的 PERV 监测

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-07 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13491

Joachim Denner

{"title":"Monitoring for PERV Following Xenotransplantation.","authors":"Joachim Denner","doi":"10.3389/ti.2024.13491","DOIUrl":"10.3389/ti.2024.13491","url":null,"abstract":"Porcine endogenous retroviruses (PERVs) are integrated in the genome of all pigs. PERV-A, PERV-B and PERV-C can be released as infectious virus particles and PERV-A and PERV-B can infect human cells in culture. PERV-C does not infect human cells, but high-titer recombinant PERV-A/C can infect them. Retroviruses are able to induce immunosuppression and/or tumors in the infected host. Numerous methods have been developed to study PERV in donor pigs. No PERV infections were observed in infection experiments as well as in preclinical and clinical xenotransplantation trials. Despite this, several strategies have been developed to prevent PERV infection of the recipient. PCR-based and immunological methods are required to screen xenotransplant recipients. Since the proviruses are integrated into the pig genome, PERV infection has to be distinguished from microchimerism, e.g., the presence of pig cells in the recipient, which is common in xenotransplantation. Sensitive PCR methods using pig short interspersed nuclear elements (SINE) sequences allow to detect pig cells easily. Virus infection can also be detected by an increase of viral genomic or mRNA in human cells. The method of choice, however, is to screen for specific antibodies against PERV using different recombinant PERV proteins, purified viruses or peptides.","PeriodicalId":23343,"journal":{"name":"Transplant International","volume":"37 ","pages":"13491"},"PeriodicalIF":2.7,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11491343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142475828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Non-Standard Risk Donors and Risk of Donor-Derived Infections: From Evaluation to Therapeutic Management. 非标准风险捐献者与捐献者感染风险：从评估到治疗管理。

IF 2.7 3区医学

Transplant International Pub Date : 2024-10-02 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.12803

Paolo A Grossi, Cameron Wolfe, Maddalena Peghin

引用次数: 0

Transplant Trial Watch. 移植试验观察。

IF 2.7 3区医学

Transplant International Pub Date : 2024-09-30 eCollection Date: 2024-01-01 DOI: 10.3389/ti.2024.13746

John M O'Callaghan, Simon Knight, Keno Mentor

引用次数: 0